July 21, 2014 - The University of California Center for Accelerated Innovation
(UC CAI) invites applications from UC investigators for the development of novel technologies that address heart, lung and blood diseases. This opportunity will support a broad range of drugs, devices (including wireless devices), diagnostics and tools with high potential of becoming commercially viable products that address an unmet need.
UC CAI is a collaboration of the five UC medical campuses, including UC San Diego, to accelerate the translation of UC discoveries to benefit patients with heart, lung and blood diseases.
Technology Development Awards provide grant and local support worth up to $200,000 for a period of up to two years, as well as mentoring and project management support. It is anticipated that five to six awards will be made. NIH guidelines for annual and end-of-project reporting will apply. Carry forward of funds is not allowed.
Faculty in all series and ranks at UC Davis, UC Irvine, UCLA, UC San Diego, and UC San Francisco are eligible. Postdoctoral scholars are eligible to submit applications as Co-PI with a faculty PI.
Innovators will submit a short pre-application online through the Center’s website, uccai.ctsi.ucla.edu. The pre-application may be submitted Aug. 18-22 only. Submission closes at 5 p.m. on Aug. 22.
To review the RFA, please go to UC CAI Funding Opportunities
UC CAI is administered from UCLA and is supported by the National Institute of Heart, Lung and Blood Diseases. It is one of three such centers in the U.S.